Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 31.64 Million AUD | 11.1% |
| 2023 | 28.48 Million AUD | 402.03% |
| 2022 | 5.67 Million AUD | -98.06% |
| 2021 | 292.77 Million AUD | -17.11% |
| 2020 | 353.21 Million AUD | 10.9% |
| 2019 | 318.5 Million AUD | -14.87% |
| 2018 | 374.13 Million AUD | 14.37% |
| 2017 | 327.12 Million AUD | 323.91% |
| 2016 | 77.16 Million AUD | 24.95% |
| 2015 | 61.75 Million AUD | 35.26% |
| 2014 | 45.65 Million AUD | 16.39% |
| 2013 | 39.22 Million AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 1.02 Million AUD | 0.0% |
| 2009 | - AUD | -100.0% |
| 2008 | 2222.00 AUD | -60.01% |
| 2007 | 5556.00 AUD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 31.64 Million AUD | 5.4% |
| 2024 Q4 | 31.64 Million AUD | 0.0% |
| 2024 Q2 | 30.01 Million AUD | 0.0% |
| 2024 FY | 31.64 Million AUD | 11.1% |
| 2024 Q1 | 33.1 Million AUD | 5.4% |
| 2023 Q2 | 4.33 Million AUD | 0.0% |
| 2023 FY | 28.48 Million AUD | 402.03% |
| 2023 Q1 | 4.33 Million AUD | -23.55% |
| 2023 Q4 | 5.67 Million AUD | -82.85% |
| 2023 Q3 | 33.07 Million AUD | 662.69% |
| 2022 Q2 | 326.69 Million AUD | -1.8% |
| 2022 Q4 | 5.67 Million AUD | 0.0% |
| 2022 FY | 5.67 Million AUD | -98.06% |
| 2022 Q3 | 5.67 Million AUD | -98.26% |
| 2022 Q1 | 332.69 Million AUD | 13.63% |
| 2021 Q1 | 287.4 Million AUD | -18.63% |
| 2021 FY | 292.77 Million AUD | -17.11% |
| 2021 Q2 | 279.99 Million AUD | -2.58% |
| 2021 Q4 | 292.77 Million AUD | 0.0% |
| 2021 Q3 | 292.77 Million AUD | 4.57% |
| 2020 Q4 | 353.21 Million AUD | 0.0% |
| 2020 FY | 353.21 Million AUD | 10.9% |
| 2020 Q2 | 333.78 Million AUD | -2.8% |
| 2020 Q3 | 353.21 Million AUD | 5.82% |
| 2020 Q1 | 343.38 Million AUD | 7.81% |
| 2019 Q4 | 318.5 Million AUD | 0.0% |
| 2019 FY | 318.5 Million AUD | -14.87% |
| 2019 Q3 | 318.5 Million AUD | -5.71% |
| 2019 Q1 | 337.77 Million AUD | -9.72% |
| 2019 Q2 | 337.77 Million AUD | 0.0% |
| 2018 Q4 | 374.13 Million AUD | 0.0% |
| 2018 Q2 | 359.08 Million AUD | 0.0% |
| 2018 FY | 374.13 Million AUD | 14.37% |
| 2018 Q1 | 359.08 Million AUD | 9.77% |
| 2018 Q3 | 374.13 Million AUD | 4.19% |
| 2017 Q3 | 327.12 Million AUD | 4.49% |
| 2017 Q2 | 313.07 Million AUD | 0.0% |
| 2017 Q4 | 327.12 Million AUD | 0.0% |
| 2017 Q1 | 313.07 Million AUD | 305.71% |
| 2017 FY | 327.12 Million AUD | 323.91% |
| 2016 FY | 77.16 Million AUD | 24.95% |
| 2016 Q1 | 64.79 Million AUD | 4.92% |
| 2016 Q4 | 77.16 Million AUD | 1.1% |
| 2016 Q3 | 76.33 Million AUD | 17.8% |
| 2016 Q2 | 64.79 Million AUD | 0.0% |
| 2015 Q3 | 61.75 Million AUD | 21.85% |
| 2015 Q2 | 50.68 Million AUD | 0.0% |
| 2015 FY | 61.75 Million AUD | 35.26% |
| 2015 Q4 | 61.75 Million AUD | 0.0% |
| 2015 Q1 | 50.68 Million AUD | 11.01% |
| 2014 FY | 45.65 Million AUD | 16.39% |
| 2014 Q2 | 49.31 Million AUD | 0.0% |
| 2014 Q3 | 45.65 Million AUD | -7.43% |
| 2014 Q4 | 45.65 Million AUD | 0.0% |
| 2014 Q1 | 49.31 Million AUD | 25.73% |
| 2013 FY | 39.22 Million AUD | 0.0% |
| 2013 Q3 | 39.22 Million AUD | 0.0% |
| 2013 Q4 | 39.22 Million AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | 1.02 Million AUD | 0.0% |
| 2010 FY | 1.02 Million AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | -100.0% |
| 2008 FY | 2222.00 AUD | -60.01% |
| 2008 Q4 | 2222.00 AUD | 0.0% |
| 2007 FY | 5556.00 AUD | 0.0% |
| 2007 Q4 | 5556.00 AUD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 99.858% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 99.917% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | 70.445% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 99.842% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -63.166% |